Lymphomas

Otolaryngologic Clinics of North America

Volumn 36, Issue 4, 2003, Pages 625-646

  Nayak, Laxmeesh M ^a   Deschler, Daniel G ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; BLEOMYCIN; CANCER VACCINE; CHIMERIC CD30 CD25 MONOCLONAL ANTIBODY; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; EPRATUZUMAB; HEMOPOIETIC GROWTH FACTOR; LYMPHOMA VACCINE; PREDNISONE; RITUXIMAB; UNCLASSIFIED DRUG; VINBLASTINE; VINCRISTINE;

CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER DIAGNOSIS; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; HODGKIN DISEASE; HUMAN; LEUKEMIA; LYMPHOMA; LYMPHOPROLIFERATIVE DISEASE; NONHODGKIN LYMPHOMA; NUCLEAR MAGNETIC RESONANCE IMAGING; POSTTRANSPLANTATION LYMPHOPROLIFERATIVE DISORDER; PROGNOSIS; RADIATION INJURY; REVIEW; SECOND CANCER;

EID: 0041802837     PISSN: 00306665     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0030-6665(03)00033-1     Document Type: Review

References (86)

1. Braggi D. Radiology of the lymphomas. Curr Probl Diagn Radiol 1997;16(4):177-206.
2. Cancer facts and figures. Atlanta, GA: American Cancer Society, 2002. p. 6.
3. Carbone P, Kaplan H, Musshoff K, et al. Report of the committee on Hodgkin's disease staging classification. Cancer Res 1971;31(11):1860-1.
4. Hermans R, Horvath M, De Schrijver T, et al. Extranodal non-Hodgkin lymphoma of the head and neck. J Belge Radiol 1994;77(2):72-7.
5. Liang R, Todd D, Chan T, et al. Treatment outcome and prognostic factors for primary nasal lymphoma. J Clin Oncol 1995;13(3):666-70.
6. Weisenburger D. Epidemiology of non-Hodgkin's lymphoma: recent findings regarding and emerging epidemic. Ann Oncol 1994;5(Suppl 1):S19-24.
7. American Cancer Society. Non-Hodgkin's lymphoma. Available at: http://www.cancer. org. Accessed May 15, 2002.
8. Powles T, Matthews G, Bower M. AIDS related systemic non-Hodgkin's lymphoma. Sex Transm Infect 2000;76(5):335-41.
9. Kaplan L. HIV-associated lymphoma. AIDS Clin Rev 1993-1994;145-66.
10. Kaplan L, Abrams D, Feigal E, et al. AIDS-associated non-Hodgkin's lymphoma in San Francisco. JAMA 1989;261(5):719-24.
11. Zapater E, Bagan J, Campos A, et al. Non-Hodgkin's lymphoma of the head and neck in association with HIV infection. Ann Otolaryngol Chir Cervicofac 1996;113(2):69-72.
12. Clarke C, Glaser S. Epidemiologic trends in HIV-associated lymphomas. Curr Opin Oncol 2001;13(5):354-9.
13. Biggar R. AIDS-related cancers in the era of highly active antiretroviral therapy. Oncology (Huntington) 2001;15(4):439-448; discussion 448-9.
14. Finn D. Lymphoma of the head and neck and acquired immunodeficiency syndrome: clinical investigation and immunohistological study. Laryngoscope 1995;105(4 Pt 2 Suppl 68):1-18.
15. Kelly S, Geraghty J, Neale GH. Pylori, gastic carcinoma, and MALT lymphoma [letter]. Lancet 1994;343(8894):418.
16. Hyjek E, Smith W, Isaacson P. Primary B-cell lymphoma of salivary glands and its relationship to myoepithelial sialoadenitis. Hum Pathol 1988;19(7):766-76.
17. Hyek E, Isaacson P. Primary B cell lymphoma of the thyroid and its relationship to Hashimoto's thyroiditis. Hum Pathol 1988;19(11):1315-26.
18. Penn I. The incidence of malignancies in transplant recipients. Transplant Proc 1975;7(2):323-6.
19. Cobleigh MA, Kennedy JL. Non-Hodgkin's lymphomas of the upper aerodigestive tract and salivary glands. Otolaryngol Clin N Am 1986;19(4):685-710.
20. Isaacson P. The current status of lymphoma classification. Br J Haematol 2000;109(2):258-66.
21. Rappaport H. Tumors of the hematopoietic system. In: Atlas of tumor pathology, section iii, fascicle 8. Washington (DC): Armed Forces Institute of Pathology; 1966.
22. Lukes R, Collins R. Immunologic characterization of human malignant lymphomas. Cancer 1974;34(4):1488-503.
23. Non-Hodgkin's Lymphoma Pathologic Classification Project. National Cancer Institute sponsored classifications of non-Hodgkin's lymphomas: summary and description of a working formulation for clinical usage. Cancer 1982;49(10):2112-35.
24. Jacobs C, Weiss L, Hoppe R. The management of extranodal head and neck lymphoma. Arch Otolaryngol Head Neck Surg 1986;112(6):654-8.
25. Gerard-Marand R, Hamlin I, Lennert K. Classification of non-Hodgkin's lymphoma. Lancet 1974;2(7877):405-8.
26. Stansfeld A, Diebold J, Noel H, et al. Updated Kiel classification for lymphomas. Lancet 1988;1(8580):292-3.
27. Harris N, Jaffe E, Stein H, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 1994; 84(5):1361-92.
28. Harris N, Jaffe E, Diebold J, et al. Lymphoma classification-from controversy to consensus: the REAL and WHO classification of lymphoid neoplasms. Ann Oncol 2000;11(Suppl. 1):S3-10.
29. Clark R, Fitzpatrick P, Gospodarowicz M. Extranodal malignant lymphomas of the head and neck. J Otolaryngol 1983;12(4):239-45.
30. Urquhart A, Berg R. Hodgkin's and non-Hodgkin's lymphoma of the head and neck. Laryngoscope 2001;111(9):1565-9.
31. Freeman C, Berg J, Cutler S. Occurrence and prognosis of extranodal lymphoma. Cancer 1972;29(1):252-60.
32. Banfi A, Bonadonna G, Ricci S, et al. Malignant lymphomas of Waldeyer's ring: natural history and survival after radiotherapy. BMJ 1972;3(819):140-3.
33. Morton R, Sillars H, Benjamin C. Incidence of "unsuspected" extranodal head and neck lymphoma. Clin Otolaryngol 1992;17(5):373-5.
34. Isaacson P, Wright D. Extranodal malignant lymphoma arising from mucosa-associated lymphoid tissue. Cancer 1984;53(11):2515-24.
35. Zukerberg L, Medeiros L, Ferry J, et al. Diffuse low-grade B-cell lymphomas. Four clinically distinct subtypes defined by a combination of morphologic and immunophenotypic features. Am J Clin Pathol 1993;100(4):373-85.
36. Bhattacharyya N, Frankenthaler R, Gomolin H, et al. Clinical and pathologic characterization of mucosa-associated lymphoid tissue lymphoma of the head and neck. Ann Otol Rhinol Laryngol 1998;107(9 Pt 1):801-6.
37. Voulgarelis M, Moutsopoulos H. Malignant lymphoma in primary Sjogren's syndrome. Isr Med Assoc J 2001;3(10):761-6.
38. Armitage JO. Treatment of non-Hodgkin's lymphoma. N Engl J Med 1993;328(14): 1023-30.
39. Aisenberg C. Coherent view of non-Hodgkin's lymphoma [review]. J Clin Oncol 1995;13(10):2656-75.
40. Stein R, Ultmann J, Byrne Jr. G, et al. Bone marrow involvement in non-Hodgkin's lymphoma. Implications for staging and therapy. Cancer 1976;37(2):629-36.
41. Jones S, Fuks Z, Kaplan H, et al. Non-Hodgkin's lymphomas. V. Results of radiotherapy. Cancer 1973;32(3):682-91.
42. Jones S. Autoimmune disorders and malignant lymphoma. Cancer 1973;31(5):1092-8.
43. Burkitt D. A sarcoma involving the jaws in African children. Br J Surg 1958;46:218-23.
44. Hecht J, Aster J. Molecular biology of Burkitt's lymphoma. J Clin Oncol 2000; 18(21):3707-21.
45. Wang M, Strasnick B, Zimmerman M. Extranodal American Burkitt's lymphoma of the head and neck. Arch Otolaryngol Head Neck Surg 1992;118(2):193-9.
46. Horning S, Rosenberg S. The natural history of initially untreated low-grade non-Hodgkin's lymphomas. N Engl J Med 1984;311(23):1471-5.
47. Kimby E, Bjorkholm M, Gahrton G, et al. Chlorambucil/prednisone vs. CHOP in symptomatic low-grade non-Hodgkin's lymphomas: a randomized trial from the Lymphoma Group of Central Sweden. Ann Oncol 1994;5(Suppl 2):67-71.
48. Portlock C, Rosenberg S. No initial therapy for stage III and IV non-Hodgkin's lymphomas of favorable histologic types. Ann Intern Med 1979;90(1):10-3.
49. Marion J. Diagnosis and treatment of lymphomas. In: Thawley SE, Panje WR, Batskis JG, et al, editors. Comprehensive management of head and neck tumors. 1st edition. Philadelphia: WB Saunders; 1987. p. 1840-53.
50. Vaughan Hudson B, Vaughan Hudson G, MacLenan K, et al. Clinical stage 1 non-Hodgkin's lymphoma: long-term follow-up of patients treated by the British National Lymphoma Investigation with radiotherapy alone as initial therapy. Br J Cancer 1994;69(6):1088-93.
51. Ruijs C, Dekker A, van Kempen-Harteveld M, et al. Treatment of localized non-Hodgkin's lymphomas of the head and neck. Cancer 1994;74(2):703-7.
52. Nathu R, Mendenhall N, Almasri N, et al. Non-Hodgkin's lymphoma of the head and neck: a 30-year experience at the University of Florida. Head Neck 1999;21(3): 247-54.
53. Czuczman M. Immunochemotherapy in indolent non-Hodgkin's lymphoma. Semin Oncol 2002;29(2 Suppl 6):11-7.
54. Coiffier B. Rituximab in combination with CHOP improves survival in elderly patients with aggressive non-Hodgkin's lymphoma. Semin Oncol 2002;29(2 Suppl 6):18-22.
55. McCune S, Gockerman H, Rizzieri D. Monoclonal antibody therapy in the treatment of non-Hodgkin lymphoma. JAMA 2001;286(10):1149-52.
56. Press O, Leonard J, Coiffier B, et al. Immunotherapy of non-Hodgkin's lymphomas. Hematology 2001;221-40.
57. Vose J, Link B, Grossbard M, et al. Phase II study of rituximab in combination with CHOP chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma. J Clin Oncol 2001;19(2):389-97.
58. Kimby E. Beyond immunochemotherapy: combinations of rituximab with cytokines interferon-alpha2a and granulocyte-macrophage colony stimulating factor. Semin Onco 2002;29(2 Suppl 6):7-10.
59. Goldenberg D. Targeted therapy of cancer with radiolabeled antibodies. J Nucl Med 2002;43(5):693-713.
60. Veelken H, Osterroth F. Vaccination strategies in the treatment of lymphomas. Oncology 2002;62(3):187-200.
61. Rozman C, Montserrat E. Current concepts: chronic lymphocytic leukemia. N Engl J Med 1995;333(16):1052-7.
62. Harris NL. Hodgkin's lymphomas: classification, diagnosis, and grading. Semin Hematol 1999;36(3):220-32.
63. Urba W, Longo D. Hodgkin's disease. N Engl J Med 1992;326(10):678-87.
64. Pileri SA, Ascani S, Leoncini L, et al. Hodgkin's lymphoma: the pathologist's viewpoint. J Clin Pathol 2002;55(3):162-76.
65. Mason DY, Banks PM, Chan J, et al. Nodular lymphocyte predominance Hodgkin's disease: a distinct clinicopathologic entity. Am J Surg Pathol 1994;18(5):526-30.
66. Mead GM. Malignant lymphomas and chronic lymphocytic leukaemia. BMJ 1997; 314(7087):1103-6.
67. Bacchi CE, Dorfman RF, Hope RT, et al. Metastatic carcinoma in lymph nodes simulating "syncitial variant" of nodular sclerosing Hodgkin's disease. Am J Clin Pathol 1991; 96(5):589-93.
68. Zarate-Osorno A, Jaffe E, Medeiros J. Metastatic nasopharyngeal carcinoma initially presenting as cervical lymphadenopathy: a report of two cases that resembled Hodgkin's disease. Arch Pathol Lab Med 1992;116(8):862-5.
69. Poluri A, Shah K, Carew J, et al. Hodgkin's disease of the head and neck in human immunodeficiency virus-infected patients. Am J Otolaryngol 2002;23(1):12-6.
70. Josting A, Diehl V. Early-stage Hodgkin's disease. CurrOncol Rep 2001;3(3):279-84.
71. Freedman AS, Nadler LM. Malignancies of lymphoid cells. In: Fauci AS, Braunwald E, Isselbacher KJ, et al, editors. Harrison's principles of internal medicine. 14th edition. New York: McGraw-Hill; 1998. p. 695-712.
72. Stupp R, Vokes EE. Diagnosis and treatment of lymphomas. In: Thawley SE, Panje WR, Batskis JG, et al, editors. Comprehensive management of head and neck tumors. 2nd edition. Philadelphia: WB Saunders; 1999. p. 1919-30.
73. Fung H, Nademanee A. Approach to Hodgkin's lymphoma in the new millennium. Hematol Oncol 2002;20(1):1-15.
74. Josting A, Wolf J, Diehl V. Hodgkin disease: prognostic factors and treatment strategies. Curr Opin Oncol 2000;12(5):403-11.
75. Schmitz N, Pfistner B, Sextro M, et al. German Hodgkin's Lymphoma Study Group. Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial. Lancet 2002;359(9323):2065-71.
76. Longo DL. The use of chemotherapy in the treatment of Hodgkin's disease. Semin Oncol 1990;17(6):716-35.
77. Wahl A, Klussman K, Thompson J, et al. The anti-CD30 monoclonal antibody SGN-30 promotes growth arrest and DNA fragmentation in vitro and affects antitumor activity in models of Hodgkin's disease. Cancer Res 2002;62(13):3736-42.
78. Matthey B, Engert A, Barth S. Recombinant immunotoxins for the treatment of Hodgkin's disease. Int J Mol Med 2000;6(5):509-14.
79. Varady E, Deak B, Molnar Z, et al. Second malignancies after treatment for Hodgkin's disease. Leuk Lymphoma 2001;42(6):1275-81.
80. Starzl T. In discussion: Murray J, Wilson R, Tilney N. Five years of experience in renal transplantation with immunosuppressive drugs: survival, function, complications, and the role of lymphocyte depletion by thoracic duct fistula. Ann Surg 1968;168(3):416-35.
81. McDiarmid S, Jordan S, Kim G, et al. Prevention and preemptive therapy of posttransplant lymphoproliferative disease in pediatric liver recipients. Transplantation 1998;66(12):1604-11.
82. Williamson R, Huang R, Shapiro N. Adenotonsillar histopathology after organ transplantation. Otolaryngol Head Neck Surg 2001;125(3):231-40.
83. Deschler D, Osorio R, Ascher N, et al. Posttransplantation lymphoproliferative disorder in patients under primary tacrolimus (FK 506) immunosuppression. Arch Otolaryngol Head Neck Surg 1995;121(9):1037-41.
84. Swinnen L. Organ transplant-related lymphoma. Curr Treat Options Oncol 2001;2(4): 301-8.
85. Nalesnik M, Demetris A, Fung J, et al. Lymphoproliferative disorders arising under immunosuppression with FK506. Transplant Proc 1991;23(1 Pt. 2):1108-10.
86. Sculerati N, Arriaga M. Otolaryngologic management of post transplant lymphoproliferative disease in children. Ann Otol Rhinol Laryngol 1990;99(6 Pt. 1):445-50.